MedTrace Logo

Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs

NCT00050921 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-11-01

No results posted yet for this study

Summary

This study is designed to evaluate the ability of growth hormone (GH, also known as somatropin) to increase CD4+ cell counts in patients taking anti-HIV drugs. The study is targeted toward patients with low levels of HIV who continue to have low CD4+ cell counts.

Conditions

  • HIV Infections

Interventions

DRUG

somatropin

BIOLOGICAL

Hepatitis A virus, inactivated

DRUG

Keyhole-Limpet Hemocyanin

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Kimberly Smith, M.D., MPH · Rush Medical College of Rush University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2005-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00050921 on ClinicalTrials.gov